Appearance of primary lymphoid malignancies on lymphotropic nanoparticle-enhanced magnetic resonance imaging using ferumoxtran-10

Clinical Imaging

Volumn 34, Issue 6, 2010, Pages 448-452

  Saokar, Anuradha ^a   Gee, Michael S ^a   Islam, Tina ^a   Mueller, Peter R ^a   Harisinghani, Mukesh G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Ferumoxtran 10; Lymphoma; Lymphotropic nanoparticle enhanced MRI; MRI; Superparamagnetic iron oxide nanoparticles

Indexed keywords

BREAST CANCER; CLINICAL TRIAL; CONTROL GROUPS; FERUMOXTRAN-10; LYMPH NODE; LYMPHOID MALIGNANCIES; LYMPHOMA; MRI; NODAL METASTASIS; SIGNAL INTENSITIES; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES;

BODY FLUIDS; IRON OXIDES; NANOMAGNETICS; NANOPARTICLES; ONCOLOGY; PATHOLOGY; RESONANCE; SIGNAL TO NOISE RATIO; SUPERPARAMAGNETISM;

MAGNETIC RESONANCE IMAGING;

FERUMOXTRAN 10; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMAGE PROCESSING; IMAGE QUALITY; INCIDENTAL FINDING; LEUKEMIA; LYMPH NODE METASTASIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX RATIO; SIGNAL NOISE RATIO; SIGNAL PROCESSING;

AGED; AGED, 80 AND OVER; CONTRAST MEDIA; DEXTRANS; FEMALE; HUMANS; IMAGE ENHANCEMENT; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOMA; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 78449286970     PISSN: 08997071     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinimag.2009.09.008     Document Type: Article

References (10)

1. Harisinghani MG, Dixon WT, Saksena MA, Brachtel E, Blezek DJ, Dhawale PJ, Torabi M, Hahn PF MR lymphangiography: imaging strategies to optimize the imaging of lymph nodes with ferumoxtran-10. Radiographics 2004, 24:867-878.
2. Anzai Y, Piccoli CW, Outwater EK, et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 2003, 228:777-788.
3. Terris MK, Hausdorff J, Freiha FS Hematolymphoid malignancies diagnosed at the time of radical prostatectomy. J Urol 1997, 158:1457-1459.
4. Eisenberger CF, Walsh PC, Eisenberger MA, Chow NH, Partin AW, Mostwin JL, Marshall FF, Epstein JI, Schoenberg M Incidental non-Hodgkin's lymphoma in patients with localized prostate cancer. Urology 1999, 53:175-179.
5. Harris NL, Jaffe ES, Kiebold J, Flandrin G, Muller-Hermelink HK, Vardiman J Lymphoma classification-from controversy to consensus: the REAL and WHO Classification of lymphoid neoplasms. Ann Oncol 2000, 11(Suppl 1):S3-S10.
6. Ballester OF, Moscinski L, Spiers A, Balducci L Non-Hodgkin's lymphoma in the older person: a review. J Am Geriatr Soc 1993, 41:1245-1254.
7. Weir EG, Epstein JI Incidental small lymphocytic lymphoma/chronic lymphocytic leukemia in pelvic lymph nodes excised at radical prostatectomy. Arch Pathol Lab Med 2003, 127:567-572.
8. Heidenreich A, Varga Z, Von Knobloch R Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002, 167:1681-1686.
9. Campbell SC, Klein EA, Levin HS, Piedmonte MR Open pelvic lymph node dissection for prostate cancer: a reassessment. Urology 1995, 46:352-355.
10. Poulsen AL, Horn T, Steven K Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol 1998, 160:2015-2019.